Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | SEE REMARKS | January 21, 2026 | January 23, 2026 |
| Radius Health, Inc.RDUS · Entity 124173 | Sr. VP, General Counsel | February 22, 2019 | February 26, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date January 21, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2036-01-20 | Direct | 250,000 |
Reported balance
After 2026-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-21 · Grant · Acquired 250,000 · Balance 250,000 F1: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Radius Health, Inc.
Report date February 22, 2019 · Filed February 26, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,944 |
Reported balance
After 2019-02-22 transaction · row 1
1 source rowRow 1 · 2019-02-22 · Grant · Acquired 15,000 · Balance 17,944 F1: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in four substantially equal annual installments on each of the first four anniversaries of the grant date of February 22, 2019, subject to continued service with RDUS through such dates. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.18 · Expires 2029-02-22 | Direct | 55,000 |
Reported balance
After 2019-02-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-22 · Grant · Acquired 55,000 · Balance 55,000 F2: 25% of the shares subject to the stock option shall vest on February 22, 2020, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in four substantially equal annual installments on each of the first four anniversaries of the grant date of February 22, 2019, subject to continued service with RDUS through such dates.
F2: 25% of the shares subject to the stock option shall vest on February 22, 2020, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2026 Filed Jan 23, 2026 21:05 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001637054-26-000002 · form4-01232026_040109.xml · derivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2036-01-20 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 21:35 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001415889-25-002486 · form4-01312025_090101.xml · derivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2035-01-29 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 21:35 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002486 · form4-01312025_090101.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,400 F1 · kind: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 22:38 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001415889-24-003969 · form4-02152024_100242.xml · derivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:10 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-23-022383 · tm236831-1_4seq1.xml · derivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:21 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001415889-22-001518 · form4-02172022_010257.xml · derivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 15, 2023, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:53 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,078 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001104659-21-065995 · tm2116337-1_4seq1.xml · derivative · entry 5 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,474 Underlying: Common Stock · 4,078 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:53 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 351 | $28.20 | $9,899.74 |
DisclosureSEC source: 0001104659-21-065995 · tm2116337-1_4seq1.xml · nonDerivative · entry 4 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.12 to $28.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:53 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 2,566 | $27.90 | $71,596.02 |
DisclosureSEC source: 0001104659-21-065995 · tm2116337-1_4seq1.xml · nonDerivative · entry 3 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,751 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.095 to $28.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:53 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 1,161 | $26.11 | $30,309.07 |
DisclosureSEC source: 0001104659-21-065995 · tm2116337-1_4seq1.xml · nonDerivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,317 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.81 to $26.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:53 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 4,078 | $3.20 | $13,049.60 |
DisclosureSEC source: 0001104659-21-065995 · tm2116337-1_4seq1.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 00:45 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 179,915 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000899243-21-015666 · doc4.xml · derivative · entry 3 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,552 Underlying: Common Stock · 4,078 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 00:45 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 4,078 | $25.00 | $101,950.00 |
DisclosureSEC source: 0000899243-21-015666 · doc4.xml · nonDerivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 00:45 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 4,078 | $3.20 | $13,049.60 |
DisclosureSEC source: 0000899243-21-015666 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:56 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,078 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000899243-21-011958 · doc4.xml · derivative · entry 3 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,630 Underlying: Common Stock · 4,078 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:56 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 4,078 | $26.36 | $107,493.23 |
DisclosureSEC source: 0000899243-21-011958 · doc4.xml · nonDerivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.8375 to $26.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:56 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 4,078 | $3.20 | $13,049.60 |
DisclosureSEC source: 0000899243-21-011958 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 00:06 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $28.69 | $0.00 |
DisclosureSEC source: 0000899243-21-007450 · doc4.xml · derivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 02:24 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,078 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000899243-21-006454 · doc4.xml · derivative · entry 4 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,708 Underlying: Common Stock · 4,078 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 02:24 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 307 | $27.66 | $8,492.20 |
DisclosureSEC source: 0000899243-21-006454 · doc4.xml · nonDerivative · entry 3 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.525 to $28.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 02:24 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 3,771 | $27.19 | $102,532.74 |
DisclosureSEC source: 0000899243-21-006454 · doc4.xml · nonDerivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,707 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.47 to $27.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 12, 2021 Filed Feb 13, 2021 02:24 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 4,078 | $3.20 | $13,049.60 |
DisclosureSEC source: 0000899243-21-006454 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.86 | $0.00 |
DisclosureSEC source: 0000899243-21-002119 · doc4.xml · derivative · entry 10 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,251 Underlying: Common Stock · 7,500 shares Expires 2029-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on December 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,078 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000899243-21-002119 · doc4.xml · derivative · entry 9 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,786 Underlying: Common Stock · 4,078 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 7,511 | $36.00 | $270,395.25 |
DisclosureSEC source: 0000899243-21-002119 · doc4.xml · nonDerivative · entry 8 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.95 to $36.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 100 | $34.13 | $3,412.50 |
DisclosureSEC source: 0000899243-21-002119 · doc4.xml · nonDerivative · entry 7 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,911 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 103 | $32.50 | $3,347.23 |
DisclosureSEC source: 0000899243-21-002119 · doc4.xml · nonDerivative · entry 6 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,011 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.495 to $32.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 147 | $31.91 | $4,690.43 |
DisclosureSEC source: 0000899243-21-002119 · doc4.xml · nonDerivative · entry 5 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,114 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.46 to $32.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 1,669 | $30.50 | $50,911.68 |
DisclosureSEC source: 0000899243-21-002119 · doc4.xml · nonDerivative · entry 4 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,261 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.335 to $30.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 2,048 | $29.92 | $61,283.53 |
DisclosureSEC source: 0000899243-21-002119 · doc4.xml · nonDerivative · entry 3 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,930 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.315 to $30.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 7,500 | $10.86 | $81,450.00 |
DisclosureSEC source: 0000899243-21-002119 · doc4.xml · nonDerivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 4,078 | $3.20 | $13,049.60 |
DisclosureSEC source: 0000899243-21-002119 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 21:46 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,400 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000899243-20-035424 · doc4.xml · derivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,864 Underlying: Common Stock · 5,400 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 21:46 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 5,400 | $3.20 | $17,280.00 |
DisclosureSEC source: 0000899243-20-035424 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 00:41 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,078 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000899243-20-034188 · doc4.xml · derivative · entry 3 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,264 Underlying: Common Stock · 4,078 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 00:41 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 4,078 | $34.95 | $142,522.43 |
DisclosureSEC source: 0000899243-20-034188 · doc4.xml · nonDerivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.77 to $35.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 00:41 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 4,078 | $3.20 | $13,049.60 |
DisclosureSEC source: 0000899243-20-034188 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 21:25 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,078 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000899243-20-030996 · doc4.xml · derivative · entry 5 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,342 Underlying: Common Stock · 4,078 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 21:25 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 250 | $35.01 | $8,752.18 |
DisclosureSEC source: 0000899243-20-030996 · doc4.xml · nonDerivative · entry 4 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.935 to $35.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 21:25 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 2,261 | $34.24 | $77,417.54 |
DisclosureSEC source: 0000899243-20-030996 · doc4.xml · nonDerivative · entry 3 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,250 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.895 to $34.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 21:25 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 1,567 | $33.46 | $52,436.83 |
DisclosureSEC source: 0000899243-20-030996 · doc4.xml · nonDerivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,511 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.87 to $33.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 21:25 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 4,078 | $3.20 | $13,049.60 |
DisclosureSEC source: 0000899243-20-030996 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 20:32 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,078 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000899243-20-028186 · doc4.xml · derivative · entry 4 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,420 Underlying: Common Stock · 4,078 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 20:32 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 295 | $33.75 | $9,957.46 |
DisclosureSEC source: 0000899243-20-028186 · doc4.xml · nonDerivative · entry 3 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $33.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 20:32 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 3,783 | $32.61 | $123,373.47 |
DisclosureSEC source: 0000899243-20-028186 · doc4.xml · nonDerivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,295 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.19 to $33.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 20:32 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 4,078 | $3.20 | $13,049.60 |
DisclosureSEC source: 0000899243-20-028186 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 22:11 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,078 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000899243-20-025361 · doc4.xml · derivative · entry 5 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,498 Underlying: Common Stock · 4,078 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 22:11 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 207 | $32.55 | $6,737.83 |
DisclosureSEC source: 0000899243-20-025361 · doc4.xml · nonDerivative · entry 4 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.28 to $32.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 22:11 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 1,186 | $31.42 | $37,266.97 |
DisclosureSEC source: 0000899243-20-025361 · doc4.xml · nonDerivative · entry 3 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,207 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $31.975, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 22:11 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 2,685 | $30.76 | $82,578.25 |
DisclosureSEC source: 0000899243-20-025361 · doc4.xml · nonDerivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,393 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $31.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.